Oxford BioDynamics (Oxford BioDynamics) Total Current Assets : $8.87 Mil (As of Sep. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Oxford BioDynamics Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Oxford BioDynamics's total current assets for the quarter that ended in Sep. 2023 was $8.87 Mil.

Oxford BioDynamics Total Current Assets Historical Data

The historical data trend for Oxford BioDynamics's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxford BioDynamics Total Current Assets Chart

Oxford BioDynamics Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Total Current Assets

Get a 7-Day Free Trial

20.95

16.69

9.18

3.13

8.87

Oxford BioDynamics Semi-Annual Data
	Sep13	Sep14	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Total Current Assets	Get a 7-Day Free Trial														9.18	7.64	3.13	7.40	8.87

Oxford BioDynamics Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Oxford BioDynamics's Total Current Assets for the fiscal year that ended in Sep. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	6.498	+	1.184	+	0.339	+	0.849
	=	8.87

Oxford BioDynamics's Total Current Assets for the quarter that ended in Sep. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	6.498	+	1.184	+	0.339	+	0.849
	=	8.87

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Oxford BioDynamics (OTCPK:OXBOF) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Oxford BioDynamics's Liquidation Value for the quarter that ended in Sep. 2023 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	6.498	-	12.465	+	0.75 * 0.017	+	0.5 * 0.339
=	-5.78

Oxford BioDynamics Total Current Assets Related Terms

Thank you for viewing the detailed overview of Oxford BioDynamics's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Oxford BioDynamics (Oxford BioDynamics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxford BioDynamics PLC (OTCPK:OXBOF) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

OBD:UK

Address

Oxford Business Park South, 3140 Rowan Place, John Smith Drive, Oxford, GBR, OX4 2WB

Website

https://www.oxfordbiodynamics.com

Oxford BioDynamics PLC is a biotechnology company. The company focuses on the discovery and development of biomarkers for use within the pharmaceutical and biotechnology industry. It provides a technology platform Episwitch which aims to accelerate the drug discovery and development process and improve the success rate of therapeutic product development. Geographically, the majority of revenue is from The United Kingdom.